Johnson & Johnson (JNJ) applies for U.S. and European regulatory approval of a new...
Monday, October 8, 2012, 5:16 PM ETJohnson & Johnson (JNJ) applies for U.S. and European regulatory approval of a new manufacturing process that would provide a short-term fix to the supply shortage of its Doxil cancer drug. Under JNJ's plan, existing contract manufacturer Ben Venue Labs would produce Doxil while a second supplier would handle other tasks such as ensuring the drug is sterile.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles